Basket Study to Assess Efficacy and Safety of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Novartis Pharmaceuticals is conducting this open-label, multicenter, phase 2 basket study to assess the effectiveness and safety of Iptacopan (LNP023) in adults with persistent or chronic ITP, who are at least 18 years of age. Iptacopan is an orally administered therapy that targets the alternative complement pathway of the immune system. The drug will also be given to participants who have cold agglutinin disease, a different condition than ITP, to compare how well the drug does in both patient groups. Participants must be vaccinated against Neisseria meningitidis (meningitis) and Streptococcus pneumoniae (pneumonia) infections in addition to Haemophilus influenzae (the flu) infection. Participants will be excluded if they have secondary ITP or have used any therapies for their ITP apart from low-dose corticosteroids or a thrombopoetin receptor agonist (TPO-RA) at least four weeks before enrolling into the study.

United States, Germany, Italy, Republic of Korea, Spain, United Kingdom

Status: Recruiting

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo